Samsara BioCapital LLC Decreases Holdings in HilleVax, Inc. (NASDAQ:HLVX)

Samsara BioCapital LLC decreased its holdings in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) by 50.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 399,637 shares of the company's stock after selling 399,637 shares during the period. Samsara BioCapital LLC owned approximately 0.80% of HilleVax worth $827,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Barclays PLC lifted its position in shares of HilleVax by 14.1% during the 4th quarter. Barclays PLC now owns 47,946 shares of the company's stock worth $100,000 after buying an additional 5,913 shares in the last quarter. Northern Trust Corp grew its stake in HilleVax by 2.8% in the 4th quarter. Northern Trust Corp now owns 249,610 shares of the company's stock valued at $517,000 after purchasing an additional 6,916 shares during the period. SG Americas Securities LLC increased its position in shares of HilleVax by 61.6% during the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock valued at $38,000 after purchasing an additional 6,916 shares during the last quarter. Ieq Capital LLC raised its stake in shares of HilleVax by 71.1% during the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock worth $47,000 after purchasing an additional 9,344 shares during the period. Finally, Bank of Montreal Can grew its position in HilleVax by 47.1% during the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock valued at $74,000 after buying an additional 11,459 shares during the period. Institutional investors own 86.42% of the company's stock.

HilleVax Stock Down 3.3 %

HLVX traded down $0.07 on Monday, hitting $1.90. The company's stock had a trading volume of 95,771 shares, compared to its average volume of 221,149. The company's 50 day simple moving average is $1.70 and its 200-day simple moving average is $1.84. HilleVax, Inc. has a 12 month low of $1.34 and a 12 month high of $16.31. The firm has a market cap of $95.02 million, a P/E ratio of -0.61 and a beta of 0.86.

HilleVax (NASDAQ:HLVX - Get Free Report) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.02). Equities analysts predict that HilleVax, Inc. will post -2.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "neutral" rating and set a $2.00 price target on shares of HilleVax in a research note on Monday, March 31st. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, HilleVax has a consensus rating of "Hold" and a consensus price target of $3.00.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.